Bupropion, the active substance in Bupropion tablets, is a sustained-release antidepressant that affects dopamine and noradrenaline signalling. It is prescribed for suitable adults with major depressive disorder, while other bupropion formulations may support smoking cessation. Its benefits must be balanced against insomnia, activation, blood-pressure effects and seizure risk.
Bupropion belongs to the aminoketone antidepressant group and acts mainly as a dopamine and noradrenaline reuptake inhibitor. The regimen for the chosen strength is confirmed with a healthcare professional before starting.
Bupropion is prescribed for major depressive disorder in appropriate patients. Some bupropion formulations are also authorised for seasonal affective disorder or smoking cessation, depending on the product, indication and jurisdiction. Medsafe-approved use in New Zealand depends on the specific registered formulation and prescribing decision.
The regimen for the chosen strength is confirmed with a healthcare professional before starting.
Bupropion is prescribed for major depressive disorder in appropriate patients. Some bupropion formulations are also authorised for seasonal affective disorder or smoking cessation, depending on the product, indication and jurisdiction. Medsafe-approved use in New Zealand depends on the specific registered formulation and prescribing decision.
Bupropion may be considered when depressive symptoms include low motivation, reduced energy, poor concentration or loss of interest. It is not suitable for every form of depression, and the choice depends on previous treatment response, anxiety symptoms, sleep, seizure risk, eating-disorder history and other medicines.
Smoking cessation uses a different treatment context. Bupropion may reduce nicotine withdrawal and craving as part of a structured quit plan that includes a quit date, behavioural support and follow-up. A person should not switch between sustained-release bupropion products or use one formulation for another indication without prescriber direction.
Bupropion can support smoking cessation by reducing withdrawal symptoms and nicotine craving. It works best within a planned quit programme that includes a target quit date, practical trigger management and follow-up.
Treatment-resistant depression refers to depression that has not improved adequately after appropriate treatment trials. A psychiatrist may consider bupropion as a switch, add-on or augmentation option after reviewing diagnosis, adherence, previous adverse effects and interaction risks.
In specialist psychiatric care, bupropion may be considered alongside medicines such as aripiprazole or quetiapine. These combinations require review of seizure threshold, blood pressure, agitation, sleep and CYP2D6 interactions.
Bupropion is not a universal treatment for anxiety. Its activating effect may worsen marked anxiety, panic symptoms or insomnia in some patients.
The product is a sustained-release tablet. The regimen for the chosen strength is confirmed with a healthcare professional before starting.
Immediate-release, sustained-release and extended-release bupropion have different release patterns. The number of daily doses depends on the formulation and indication, so instructions from one bupropion product cannot automatically be applied to another.
Bupropion is contraindicated in patients with a current or previous diagnosis of bulimia or anorexia nervosa because these conditions increase seizure risk.
Bupropion is not suitable for a person with:
Bupropion is NOT for you if you have a seizure disorder, bulimia or anorexia nervosa, abrupt sedative or alcohol withdrawal, or another listed contraindication.
Common adverse effects include dry mouth, nausea, headache, restlessness and insomnia. Some effects are more noticeable during the first weeks and may settle, while persistent or severe symptoms require clinical review.
| More common effects | Urgent symptoms |
|---|---|
| Dry mouth, nausea, headache, restlessness and insomnia | Seizure, severe allergic reaction, fainting or severe confusion |
| Reduced appetite, tremor or sweating | Suicidal thoughts, severe agitation or manic symptoms |
| Anxiety or difficulty settling at night | Severe rash, facial swelling or breathing difficulty |
Dry mouth can make night-time discomfort worse. Frequent water sips, sugar-free gum and regular dental care may help. Nausea is often easier to tolerate when the prescribed dose is taken with food, unless the prescriber has given different instructions.
Insomnia deserves practical attention. Taking a later dose earlier within the prescribed schedule may help, but changing the timing should be confirmed before making the change. Caffeine, nicotine and stimulant medicines can add to restlessness.
Bupropion reduces the reuptake of dopamine and noradrenaline in the brain. Reuptake is the process by which nerve cells remove signalling chemicals after they have passed a message; inhibiting it allows signalling activity to persist for longer.
The drug has limited direct serotonergic activity compared with selective serotonin reuptake inhibitors. That difference helps explain why some patients experience fewer sexual side effects with bupropion, while others experience more restlessness, anxiety or difficulty sleeping.
Dopamine contributes to motivation, reward processing and attention. Noradrenaline contributes to alertness, arousal and concentration. Bupropion modifies both systems rather than selectively targeting serotonin.
This mechanism does not guarantee a particular mood response. Antidepressant benefit develops through changes in several neural systems, and the clinical response varies between individuals. Bupropion should not be used as a self-directed treatment for ADHD, fatigue or weight management.
The liver converts bupropion into active metabolites, including hydroxybupropion. These metabolites contribute to the medicine’s pharmacological effects and remain relevant after the parent drug has been processed.
Liver function, kidney function and interacting medicines can alter exposure. Bupropion also inhibits the CYP2D6 enzyme, which affects the handling of several psychiatric and cardiovascular medicines. These factors require medication review rather than personal dose adjustment. The FDA prescribing information describes the metabolite profile and associated precautions [1].
Several errors can reduce tolerability or increase risk:
Bupropion, SSRIs and SNRIs differ in their main neurotransmitter targets and tolerability patterns. None is suitable for every patient.
| Class | Main target and practical trade-off |
|---|---|
| Bupropion | Dopamine and noradrenaline; may cause activation, insomnia or dry mouth, with limited direct serotonergic activity |
| SSRIs | Serotonin; may cause nausea, sexual dysfunction or discontinuation symptoms in some patients |
| SNRIs | Serotonin and noradrenaline; may help selected depressive or pain-related presentations but can affect blood pressure, sleep or withdrawal symptoms |
SSRIs include sertraline, fluoxetine, citalopram and escitalopram. Serotonin is involved in mood, anxiety, appetite and gastrointestinal signalling. Sexual dysfunction and nausea can occur with SSRIs, though neither is inevitable.
SNRIs include venlafaxine and duloxetine. They influence serotonin and noradrenaline, which can be useful for some symptom patterns but may increase sweating, blood pressure or discontinuation effects.
Bupropion may suit a person who has experienced sexual adverse effects with an SSRI, yet it can be a poor fit when anxiety, panic or insomnia is prominent. The choice depends on symptoms, medical history and previous response rather than on class reputation.
Clinical prescribing decisions often balance activation against sedation. Bupropion can be useful when fatigue or sexual adverse effects are significant concerns, but insomnia, anxiety, hypertension and seizure risk may limit its role.
A physician will usually ask about seizures, head injury, eating-disorder symptoms, alcohol intake, sedative use and every current medicine before starting treatment. That history is more useful than choosing an antidepressant from a single side-effect comparison.
The sustained-release formulation also changes the practical discussion. A patient who takes the tablet late, doubles a missed dose or crushes it may experience more stimulation than expected, even when the intended daily amount has not changed.
Insomnia is a recognised adverse effect of bupropion because its activating neurotransmitter effects can interfere with sleep. The FDA prescribing information reviewed in 2023 identifies insomnia, agitation and dry mouth among reported reactions. Taking the medicine later than scheduled, consuming caffeine late in the day or combining stimulating medicines can worsen the problem. A prescriber can review dose timing and other medicines if sleep disruption persists. Seek prompt advice if insomnia is severe, persistent, or accompanied by agitation.
Bupropion sustained-release tablets may be taken with food when that matches the prescribed instructions. Food can make nausea easier to tolerate, but it does not make crushing or chewing the tablet acceptable. Medsafe product information available in 2024 supports following the formulation-specific administration directions rather than borrowing instructions from another bupropion product.
Alcohol can increase problems with mood, sleep, dizziness and seizure risk during bupropion treatment. The WHO alcohol and health information reviewed in 2023 supports discussing regular or heavy alcohol use before starting medicines that can affect the central nervous system. Abruptly stopping heavy alcohol intake can also cause withdrawal seizures and requires appropriate medical support.
Pregnancy and breastfeeding require an individual assessment of the expected benefit and potential risk. The EMA safety information reviewed in 2022 supports discussing pregnancy plans, current pregnancy and breastfeeding before treatment changes. Do not stop an established antidepressant suddenly without a planned review, because untreated depression and withdrawal can also create clinical problems.
Keep tablets in a dry place at a stable room temperature, away from excess heat, moisture and children. Medsafe consumer medicine information reviewed in 2024 supports keeping medicines in their supplied container and retaining the administration information during travel. Do not leave tablets in a hot car, bathroom with frequent steam or unlabelled travel container.
Sleep, energy or concentration may change before mood improves, while the antidepressant response commonly develops over several weeks. NICE depression guidance updated in 2022 recommends early review of response, adverse effects and suicidal thinking rather than relying on a fixed promised timetable. Contact the prescriber if symptoms worsen, activation becomes severe or there is no meaningful improvement after the planned review period.
A lack of improvement should prompt a structured review of adherence, formulation, dose timing, diagnosis, other medicines, alcohol use and adverse effects. A 2018 network meta-analysis in The Lancet found that antidepressant response and acceptability vary across medicines and patients. Do not increase, stop or combine antidepressants independently; the prescriber may reassess the treatment plan.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Jonathan, 55 - Timaru, took the sustained-release tablets for several weeks after discussing persistent low energy with his prescriber. He reported better morning motivation, although dry mouth and lighter sleep were frustrating at first.
Michael P., 54 - Christchurch, used bupropion within a smoking-cessation plan. Cravings became easier to manage, but he noticed restlessness when he drank coffee late in the day and reduced caffeine after discussing it with his healthcare team.
Harry, 56 - Blenheim, stopped treatment after experiencing worsening anxiety and insomnia during the early period. He said the main difficulty was recognising that the symptoms needed prompt review rather than waiting several more weeks.
